Mobile Site ›
Normal View

Test ID: FP73
1p36.3 Microdeletion Syndrome, FISH

Secondary ID A test code used for billing and in test definitions created prior to November 2011

88541

NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Useful For Suggests clinical disorders or settings where the test may be helpful

Aids in the diagnosis of 1p microdeletion syndrome, in conjunction with CMS/8696 Chromosome Analysis, for Congenital Disorders, Blood

 

Detecting cryptic translocation involving 1p36.3 that are not demonstrated by conventional chromosome studies

Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test

Method Name A short description of the method used to perform the test

Fluorescence In Situ Hybridization (FISH)

Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name

1p36.3 Del, FISH

Specimen Type Describes the specimen type needed for testing

Varies

Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.

Provide a reason for referral with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.

 

Forms:

1. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (Supply T576) is available in Special Instructions.

2. If not ordering electronically, submit a Cytogenetics/AFP Congenital Disorders Request Form (Supply T238) with the specimen.

 

Advise Express Mail or equivalent if not on courier service.

 

Submit only 1 of the following specimens:

                                 

Specimen Type: Amniotic fluid

Container/Tube: Amniotic fluid container

Specimen Volume: 20-25 mL

Collection Instructions:

1. Optimal timing for specimen collection is during 14 to 18 weeks of gestation, but specimens collected at other weeks of gestation are also accepted. Provide gestational age at the time of amniocentesis.

2. Discard the first 2 mL of amniotic fluid.

Additional Information:

1. Place the tubes in a Styrofoam container (Supply T329).

2. Fill remaining space with packing material.

3. Unavoidably, about 1% to 2% of mailed-in specimens are not viable.

4. Bloody specimens are undesirable. If the specimen does not grow in culture, you will be notified within 7 days of receipt.

5. Results will be reported and also telephoned or faxed, if requested.

 

Specimen Type: Autopsy

Container/Tube: Sterile container with sterile Hank's balanced salt solution (Supply T132), Ringer's solution, or normal saline

Specimen Volume: 4-mm diameter

Collection Instructions:

1. Wash biopsy site with an antiseptic soap.

2. Thoroughly rinse area with sterile water.

3. Do not use alcohol or iodine preparations.

4. Biopsy specimens are best taken by punch biopsy to include full thickness of dermis.

 

Specimen Type: Blood

Container/Tube: Green top (sodium heparin)

Specimen Volume: 5 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Other anticoagulants are not recommended and are harmful to the viability of the cells.

 

Specimen Type: Chorionic villi

Container/Tube: 15-mL tube containing 15 mL of transport media

Specimen Volume: 20-25 mg

Collection Instructions:

1. Collect specimen by the transabdominal or transcervical method.

2. Transfer the CVS to a Petri dish containing transport medium (Supply T095).

3. Using a stereomicroscope and sterile forceps, assess the quality and quantity of the villi and remove any blood clots and maternal decidua.

 

Specimen Type: Fixed cell pellet

Container/Tube: Sterile container with a 3:1 fixative (methanol:glacial acetic acid)

Specimen Volume: Entire specimen

 

Specimen Type: Products of conception or stillbirth

Container/Tube: Sterile container with sterile Hank's balanced salt solution (Supply T132), Ringer's solution, or normal saline

Specimen Volume: 1 cm(3) of placenta (including 20 mg of chorionic villi) and 1-cm(3) biopsy specimen of muscle/fascia from thigh

Collection Instructions: If a fetus cannot be specifically identified, collect villus material or tissue that appears to be of fetal origin.

Additional Information: Do not send entire fetus.

Forms: Final Disposition of Fetal/Stillborn Remains (if fetal specimen is sent) in Special Instructions.

 

Specimen Type: Skin biopsy

Container/Tube: Sterile container with sterile Hank's balanced salt solution (Supply T132), Ringer's solution, or normal saline

Specimen Volume: 4-mm diameter

Collection Instructions:

1. Wash biopsy site with an antiseptic soap.

2. Thoroughly rinse area with sterile water.

3. Do not use alcohol or iodine preparations.

4. A local anesthetic may be used.

5. Biopsy specimens are best taken by punch biopsy to include full thickness of dermis.

Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.

Amniotic Fluid: 5 mL/Autopsy, Skin Biopsy: 4 mm/Blood: 2 mL/Chorionic Villi: 5 mg/Fixed Cell Pellet: 1 pellet/Products of Conception: 1 cm(3)

Reject Due To Identifies specimen types and conditions that may cause the specimen to be rejected

Hemolysis

NA

Lipemia

NA

Icterus

NA

Other

Clotted blood

Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.

Specimen TypeTemperatureTime
VariesAmbient (preferred)
 Refrigerated 

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Chromosome 1p microdeletion syndrome is associated with a spectrum of dysmorphic features and mental retardation. The syndrome can be suspected in overweight patients with mental retardation, heart defects, and finger abnormalities. Facial features include microcephaly (small head), short neck, malformed ears, and small deep-set eyes. The phenotype is variable and depends on the size of the deletion.

 

FISH studies are highly specific and do not exclude other chromosome abnormalities. For this reason, we recommend that patients suspected of having 1p microdeletion syndrome also have conventional chromosome studies (CMS/8696 Chromosome Analysis, for Congenital Disorders, Blood) performed to rule out other chromosome abnormalities or translocations.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Interpretation Provides information to assist in interpretation of the test results

Any individual with a normal signal pattern (2 signals) in each metaphase is considered negative for a deletion in the region tested by this probe.

 

Any patient with a FISH signal pattern indicating loss of the critical region will be reported as having a deletion of the region tested by this probe. This is consistent with a diagnosis of 1p microdeletion syndrome.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

Because this FISH test is not approved by the FDA, it is important to confirm 1p microdeletion syndrome diagnoses by other established methods such as clinical history or physical evaluation.

Supportive Data

In a series of 41 patients, this FISH analysis identified a 1p36.3 deletion in 6 patients whose phenotypes were consistent with 1p microdeletion syndrome or a cytogenetic or telomere 1p deletion. Six additional patients with chromosome anomalies involving 1p, but not containing 1p36 deletion, were further characterized to define breakpoints using this probe set. This demonstrated this probe’s ability to define other chromosome 1 rearrangements in this region that are not consistent with 1p-. In 29 karyotypically normal patient specimens (peripheral blood, tissue, amniotic fluid, or chorionic villus), no deletions of the region were identified.

Clinical Reference Provides recommendations for further in-depth reading of a clinical nature

1. Shapira SK, McCaskill C, Northrup H, et al: Chromosome 1p36 deletions: the clinical phenotype and molecular characterization of a common newly delineated syndrome. Am J Hum Genet 1997;61:642-650

2. Hielstedt HA, Ballif BC, Howard LA, et al: Physical map of 1p36, placement of breakpoints in monosomy 1p36, and clinical characterization of the syndrome. Am J Hum Genet 2003;72:1200-1212

3. Heilstedt HA, Ballif BC, Howard LA, et al: Population data suggests that deletions of 1p36 are a relatively common chromosome abnormality. Clin Genet 2003;64:310-316

Method Description Describes how the test is performed and provides a method-specific reference

The identification of 1p microdeletions is based on FISH analysis of the critical region locus (TP73) on the short arm of chromosome 1 (1p36.3). Metaphase cells are examined for the presence of the critical region locus at 1p36.3 (orange signal) and the control probe (ABL2) at 1q24 (green signal). In metaphase cells with a deletion, the abnormal (deleted) chromosome 1 will exhibit only a control probe signal, while signals for both the critical region and control probes will be present on the normal chromosome 1 homologs. (Crifasi PA, Michels VV, Driscoll DJ, et al: DNA fluorescent probes for diagnosis of velocardiofacial and related syndromes. Mayo Clin Proc 1995;195[70]:1148-1153)

Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.

Samples processed Monday through Sunday. Results reported Monday through Friday, 8 a.m.-5 p.m. CST.

Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.

7 days

Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result

10 days

Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

Indefinitely

Performing Laboratory Location The location of the laboratory that performs the test

Rochester

Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

88271 x 2-DNA probe, each

88273-Chromosomal in situ hybridization, analyze 10 to 30 cells

88291-Interpretation and report

LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.

Result IDReporting NameLOINC Code
23204Specimen31208-2
23205Specimen IDN/A
CG199SourceN/A
23207Order DateN/A
CG201Reason For Referral42349-1
23209MethodIn Process
23210ResultIn Process
23211Interpretation69965-2
23212AmendmentIn Process
23213ConsultantN/A
23214Released DateN/A